Date: 2011-12-16
Type of information: Collaboration agreement
Compound: pneumococcal vaccine, Synflorix®
Company: GSK (UK) GAVI Alliance
Therapeutic area: Infectious diseases
Type agreement: supply
Action mechanism:
Disease: pneumococcal disease
Details: GSK has expanded its agreement with the GAVI Alliance in a move to help protect millions more children in the world's poorest countries from pneumococcal disease. Under this new agreement, GSK commits to provide an additional 180 million doses of its pneumococcal vaccine, Synflorix®, to GAVI over the next 12 years to help expand immunisation programmes against pneumococcal disease to 72 developing countries by 2023. This builds on the 300 million doses that GSK committed to GAVI in March 2010 through an innovative financing mechanism known as the Advance Market Commitment (AMC). In total, up to 160 million children in developing countries could now be protected with Synflorix against pneumococcal disease by 2023.
GSK has committed to provide the additional 180 million doses of Synflorix® to GAVI at a small fraction of developed world prices.
Financial terms:
Latest news:
